Galectina-3: experiencia en pacientes chilenos con diagnóstico de insuficiencia cardíaca descompensada
Background: Galectin-3 (Gal-3) is a mediator of myocardial fibrosis involved in cardiac remodeling and a potential new prognosis marker in heart failure (HF). Aim: To measure Gal-3 at the moment of discharge in patients hospitalized for HF and its association with different variables. Material and Methods: Patients hospitalized for decompensated HF from four hospitals between August 2014 and March 2015, were included. Demographic, clinical and laboratory variables were recorded at the time of admission. At discharge, a blood sample was withdrawn to measure Gal-3 and brain natriuretic propeptide (Pro-BNP). Patients were separated in two groups, according to the level of Gal-3 (using a cutoff value of 17.8 ng/mL), comparing clinical and laboratory values between groups. Results: We included 52 patients with HF aged 70 ± 17 years (42% females). Functional capacity was III-IV in 46% of patients and the ejection fraction was 34.9 ± 13.4%. Pro-BNP values at discharge were 5,323 ± 8,665 pg/mL. Gal-3 values were 23.8 ± 16.6 ng/mL. Sixty percent of patients had values over 17.8 ng/mL. Those with elevated Gal-3 levels were older (75 ±16 and 62 ± 15 years, respectively, p = 0.025) and were hypertensive in a higher proportion (90.5% and 57.1% respectively, p = 0.021). Conclusions: In patients hospitalized for HF, Gal-3 levels are higher in older and hypertensive subjects.
Main Authors: | , , , , , , , |
---|---|
Format: | Digital revista |
Language: | Spanish / Castilian |
Published: |
Sociedad Médica de Santiago
2017
|
Online Access: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872017000600734 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0034-98872017000600734 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0034-988720170006007342017-11-17Galectina-3: experiencia en pacientes chilenos con diagnóstico de insuficiencia cardíaca descompensadaRossel,VíctorDíaz-Toro,FelipeVerdejo,HugoConcepción,RobertoSepúlveda,LuisCastro,PabloVukasovic,José LuisBernales,Angie Biomarkers Galectin-3 Heart Failure Background: Galectin-3 (Gal-3) is a mediator of myocardial fibrosis involved in cardiac remodeling and a potential new prognosis marker in heart failure (HF). Aim: To measure Gal-3 at the moment of discharge in patients hospitalized for HF and its association with different variables. Material and Methods: Patients hospitalized for decompensated HF from four hospitals between August 2014 and March 2015, were included. Demographic, clinical and laboratory variables were recorded at the time of admission. At discharge, a blood sample was withdrawn to measure Gal-3 and brain natriuretic propeptide (Pro-BNP). Patients were separated in two groups, according to the level of Gal-3 (using a cutoff value of 17.8 ng/mL), comparing clinical and laboratory values between groups. Results: We included 52 patients with HF aged 70 ± 17 years (42% females). Functional capacity was III-IV in 46% of patients and the ejection fraction was 34.9 ± 13.4%. Pro-BNP values at discharge were 5,323 ± 8,665 pg/mL. Gal-3 values were 23.8 ± 16.6 ng/mL. Sixty percent of patients had values over 17.8 ng/mL. Those with elevated Gal-3 levels were older (75 ±16 and 62 ± 15 years, respectively, p = 0.025) and were hypertensive in a higher proportion (90.5% and 57.1% respectively, p = 0.021). Conclusions: In patients hospitalized for HF, Gal-3 levels are higher in older and hypertensive subjects.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.145 n.6 20172017-06-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872017000600734es10.4067/s0034-98872017000600734 |
institution |
SCIELO |
collection |
OJS |
country |
Chile |
countrycode |
CL |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-cl |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
Spanish / Castilian |
format |
Digital |
author |
Rossel,Víctor Díaz-Toro,Felipe Verdejo,Hugo Concepción,Roberto Sepúlveda,Luis Castro,Pablo Vukasovic,José Luis Bernales,Angie |
spellingShingle |
Rossel,Víctor Díaz-Toro,Felipe Verdejo,Hugo Concepción,Roberto Sepúlveda,Luis Castro,Pablo Vukasovic,José Luis Bernales,Angie Galectina-3: experiencia en pacientes chilenos con diagnóstico de insuficiencia cardíaca descompensada |
author_facet |
Rossel,Víctor Díaz-Toro,Felipe Verdejo,Hugo Concepción,Roberto Sepúlveda,Luis Castro,Pablo Vukasovic,José Luis Bernales,Angie |
author_sort |
Rossel,Víctor |
title |
Galectina-3: experiencia en pacientes chilenos con diagnóstico de insuficiencia cardíaca descompensada |
title_short |
Galectina-3: experiencia en pacientes chilenos con diagnóstico de insuficiencia cardíaca descompensada |
title_full |
Galectina-3: experiencia en pacientes chilenos con diagnóstico de insuficiencia cardíaca descompensada |
title_fullStr |
Galectina-3: experiencia en pacientes chilenos con diagnóstico de insuficiencia cardíaca descompensada |
title_full_unstemmed |
Galectina-3: experiencia en pacientes chilenos con diagnóstico de insuficiencia cardíaca descompensada |
title_sort |
galectina-3: experiencia en pacientes chilenos con diagnóstico de insuficiencia cardíaca descompensada |
description |
Background: Galectin-3 (Gal-3) is a mediator of myocardial fibrosis involved in cardiac remodeling and a potential new prognosis marker in heart failure (HF). Aim: To measure Gal-3 at the moment of discharge in patients hospitalized for HF and its association with different variables. Material and Methods: Patients hospitalized for decompensated HF from four hospitals between August 2014 and March 2015, were included. Demographic, clinical and laboratory variables were recorded at the time of admission. At discharge, a blood sample was withdrawn to measure Gal-3 and brain natriuretic propeptide (Pro-BNP). Patients were separated in two groups, according to the level of Gal-3 (using a cutoff value of 17.8 ng/mL), comparing clinical and laboratory values between groups. Results: We included 52 patients with HF aged 70 ± 17 years (42% females). Functional capacity was III-IV in 46% of patients and the ejection fraction was 34.9 ± 13.4%. Pro-BNP values at discharge were 5,323 ± 8,665 pg/mL. Gal-3 values were 23.8 ± 16.6 ng/mL. Sixty percent of patients had values over 17.8 ng/mL. Those with elevated Gal-3 levels were older (75 ±16 and 62 ± 15 years, respectively, p = 0.025) and were hypertensive in a higher proportion (90.5% and 57.1% respectively, p = 0.021). Conclusions: In patients hospitalized for HF, Gal-3 levels are higher in older and hypertensive subjects. |
publisher |
Sociedad Médica de Santiago |
publishDate |
2017 |
url |
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872017000600734 |
work_keys_str_mv |
AT rosselvictor galectina3experienciaenpacienteschilenoscondiagnosticodeinsuficienciacardiacadescompensada AT diaztorofelipe galectina3experienciaenpacienteschilenoscondiagnosticodeinsuficienciacardiacadescompensada AT verdejohugo galectina3experienciaenpacienteschilenoscondiagnosticodeinsuficienciacardiacadescompensada AT concepcionroberto galectina3experienciaenpacienteschilenoscondiagnosticodeinsuficienciacardiacadescompensada AT sepulvedaluis galectina3experienciaenpacienteschilenoscondiagnosticodeinsuficienciacardiacadescompensada AT castropablo galectina3experienciaenpacienteschilenoscondiagnosticodeinsuficienciacardiacadescompensada AT vukasovicjoseluis galectina3experienciaenpacienteschilenoscondiagnosticodeinsuficienciacardiacadescompensada AT bernalesangie galectina3experienciaenpacienteschilenoscondiagnosticodeinsuficienciacardiacadescompensada |
_version_ |
1755988556307759104 |